Skip to main content
SpringerLink
Log in

Analgetika

  • Chapter
Arzneiverordnungs-Report 2016

Zusammenfassung

Die ärztliche Verordnung von Schmerzmitteln hat in den letzten 20 Jahren eine bemerkenswerte Trendwende vollzogen. Nichtopioide Analgetika wurden 30% weniger verordnet, Opioidanalgetika dagegen dreimal so viel. Das hat dazu geführt, dass jetzt fast doppelt so viele Opioidanalgetika wie nichtopioide Analgetika verschrieben werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (1986): Bundesgesundheitsamt schränkt Anwendungsgebiet von Metamizol-haltigen Monopräparaten ein. Dtsch Ärztebl 83: 3267

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2007a): Empfehlungen zur Therapie von Tumorschmerzen. AVP-Sonderheft Therapieempfehlungen, 3. Auflage. Internet: www.akdae.de/35/10/66-Tumorschmerzen-2007-3Auflage.pdf

  • Arzneimittelkommission der deutschen Ärzteschaft (2007b): Leberschäden unter Flupirtin. Dtsch Ärztebl 104: A3200

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2012): Die unkritische Anwendung von Fentanylpflastern erhöht das Risiko für schwerwiegende Nebenwirkungen. Dtsch Ärztebl 109: A724–A725

    Google Scholar 

  • Bornemann-Cimenti H, Wejbora M, Szilagyi I, Sandner-Kiesling A (2013): Fentanyl zur Behandlung von tumorbedingten Durchbruchschmerzen. Dtsch Ärztebl 110: 271–277

    Google Scholar 

  • Budd K (1990): Experience with partial antagonists in the treatment of cancer pain. In: Doyle D (Ed). Opioids in the treatments for chronic low back pain: an update of the Cochrane Review. Spine 39: 556–563

    Google Scholar 

  • Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M (2005): Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94: 825–834

    Google Scholar 

  • Devulder J (2010): Flupirtine in pain management: pharma cological properties and clinical use. CNS Drugs 24: 867–881

    Google Scholar 

  • Drover DR, Angst MS, Valle M, Ramaswamy B, Naidu S, Stanski DR, Verotta D (2002): Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 97: 827–836

    Google Scholar 

  • European Medicines Agency (2013): Restrictions in the use of flupirtine-containing medicines—CMDh endorses PRAC recommendation. Internet: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001831.jsp&mid=WC0b01ac058001d126

  • Frampton JE (2010): Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Drugs 70: 1719–1743

    Google Scholar 

  • Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E (2006): Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174: 1589–1594

    Google Scholar 

  • Garbe E, Jobski K, Schmid U (2012): Utilisation of transdermal fentanyl in Germany from 2004 to 2006. Pharmacoepidemiol Drug Saf 21:191–198

    Google Scholar 

  • Hanks GW, De Conno F, Cherny N et al (Expert Working Group of the Research Network of the European Association for Palliative Care) (2001): Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84: 587–593

    Google Scholar 

  • Jacox A, Carr DB, Payne R et al (Agency for Health Care Policy and Research (AHCPR) Pharmacological Management) (1994): Recommendations. In: Management of cancer pain. Clinical Practice Guideline No 9. U.S. Department of Health and Human Services, Public Health Service, AHCPR Publication No 94–0592, March, Rockville

    Google Scholar 

  • Kassenärztliche Bundesvereinigung (2012a): Oxycodon/Naloxon. Wirkstoff aktuell Ausgabe 6/2012. Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Oxycodon-Naloxon.pdf

  • Kassenärztliche Bundesvereinigung (2012b): Tapentadol. Wirkstoff aktuell Ausgabe 3/2012. Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Tapentadol.pdf

  • Lauche R, Klose P, Radbruch R, Welsch P, Häuser W (2015): Opioids in chronic noncancer pain—are opioids superior to nonopioid analgesics? A systematic review and metaanalysis to efficacy, tolerability and safety in randomized head-to-head comparisons of opioids versus nonopioid

    Google Scholar 

  • analgesics of at least four weeks duration. Schmerz 29: 85–95

    Google Scholar 

  • Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K (2009): A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 13: 56–64

    Google Scholar 

  • Quigley C (2002): Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002 (1): CD003447

    Google Scholar 

  • Radbruch L, Elsner F (2005): Palliative Schmerztherapie, Cannabinoide. Internist 46: 1105–1114

    Google Scholar 

  • Ripamonti C, Fagnoni E, Campa T, Brunelli C, De Conno F (2006): Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer 14: 400–407

    Google Scholar 

  • Schubert I, Ihle P, Sabatowski R (2013): Zunahme der Opioidverordnungen in Deutschland zwischen 2000 und 2011. Dtsch Ärztebl 110: 45–51

    Google Scholar 

  • Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC (2008): Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 138: 440–449

    Google Scholar 

  • The Pain Society (2004): Recommendations for the appropriate use of opioids for persistent non-cancer pain. A consensus statement prepared on behalf of the Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Royal College of Psychiatrists. March 2004. Internet: www.britishpainsociety.org/pdf/opioids_doc_2004.pdf

  • Wiffen PJ, Derry S, Naessens K, Bell RF (2015): Oral tapentalol for cancer pain. Cochrane Database Syst Rev. 2015: CD011460

    Google Scholar 

  • Wilcock A (2009): Prolonged-release naloxone can cause systemic opioid withdrawal. Eur J Pain 13: 1001 (2009)

    Google Scholar 

  • World Health Organization (WHO) (1986): Cancer Pain Relief. World Health Organization Publications, Geneva, Switzerland

    Google Scholar 

  • World Health Organization (WHO) (1996): Cancer pain relief, 2nd edn. World Health Organization Publications, Geneva, Switzerland

    Google Scholar 

  • Zhang WY, Po AL (1996): Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain—a metaanalysis. J Clin Pharm Ther 21: 261–282

    Google Scholar 

  • Zhang WY, Po AL (1997): Do codeine and caffeine enhance the analgesic effect of aspirin? A systematic overview. J Clin Pharm Ther 22: 79–97

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, 20246, Hamburg

    Prof. Dr. med. Rainer H. Böger

  2. Institut für Pharmakologie, Toxikologie der Universität, Robert-Koch-Straße 40, 37075, Göttingen

    Prof. Dr. med. Gerhard Schmidt

Authors
  1. Prof. Dr. med. Rainer H. Böger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gerhard Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Böger, R., Schmidt, G. (2016). Analgetika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2016. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50351-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50351-5_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50350-8

  • Online ISBN: 978-3-662-50351-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation